ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review

Griffin, J. M., Rosenthal, J. L., Grodin, J. L., Maurer, M. S., Grogan, M., & Cheng, R. K. (2021). ATTR Amyloidosis: Current and Emerging Management Strategies. JACC: CardioOncology, 3(4), 488–505. https://doi.org/10.1016/j.jaccao.2021.06.006
Authors:
Jan M Griffin
Julie L Rosenthal
Justin L Grodin
Mathew S Maurer
Martha Grogan
Richard K Cheng
Affiliated Authors:
Jan M Griffin
Mathew S Maurer
Author Keywords:
6mwt, 6-minute walk test
af, atrial fibrillation
al, light chain amyloid
as, aortic stenosis
aso, antisense oligonucleotide
attr-ca, transthyretin cardiac amyloidosis
attrv, variant transthyretin cardiac amyloidosis
attrwt, wild-type transthyretin cardiac amyloidosis
cmr, cardiac magnetic resonance
dccv, direct current cardioversion
hf, heart failure
lvef, left ventricular ejection fraction
nt-probnp, n-terminal pro–b-type natriuretic peptide
sap, serum amyloid p component
tavr, transcatheter aortic valve replacement
amyloidosis
cardiomyopathy
heart failure
sirna, small interfering rna
elink
Publication Type:
Article
Unique ID:
10.1016/j.jaccao.2021.06.006
PMID:
34729521
DOI:
10.1016/j.jaccao.2021.06.006
Journal:
JACC: CardioOncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: